NCT00640211|Withdrawn
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B
PIPET B
Loading search results
PIPET B
Sponsor study identifier
observational
0
1 country
8
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThis aim of this project is to evaluate the efficacy of neuraminidase inhibitors as prophylaxis against pandemic influenza infection in patients who are prescribed a long term course in the context of a place of employment or profession. The study is observational only. The primary measure used in this study will be the incidence of symptomatic pandemic influenza in patients receiving prophylaxis. Seroconversion to pandemic influenza, the incidence of adverse events and the relative effectiveness of oseltamivir and zanamivir prophylaxis will also be examined. This project will commence upon pandemic influenza being declared in Australia, Hong Kong or Singapore. Data will be analysed as quickly as possible to help inform the continued use of neuraminidase inhibitor therapy as a cornerstone of the public health agency response to pandemic influenza.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 17, 2008
Actual (reported)March 21, 2008
Actual (reported)The primary measure used in this study will be the incidence of symptomatic pandemic influenza in patients receiving prophylaxis.
One month
Seroconversion to pandemic influenza, the incidence of adverse events and the relative effectiveness of oseltamivir and zanamivir prophylaxis will also be examined.
One month
Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
St Vincent's Hospital
Sydney, New South Wales, 2010, Australia
Prince of Wales Hospital
Sydney, New South Wales, 2031, Australia
Westmead Hospital
Sydney, New South Wales, 2145, Australia
Royal Brisbane Hospital
Brisbane, Queensland, 4000, Australia
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Flinders Medical Centre
Adelaide, South Australia, 5042, Australia
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
Dominic Dwyer
Westmead Hospital
0 participants (actual enrollment reported by the registry).
First Submitted
March 17, 2008
First Posted
March 21, 2008
Last Updated
April 24, 2012
Record last verified: 2012-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.
Royal Perth Hospital
Perth, Western Australia, 6000, Australia